374 related articles for article (PubMed ID: 30890473)
1. Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects.
Burks S; Raymick J; Robinson B; Hanig J; Sarkar S
Neurosci Lett; 2019 Jun; 703():86-95. PubMed ID: 30890473
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model.
Sarkar S; Chigurupati S; Raymick J; Mann D; Bowyer JF; Schmitt T; Beger RD; Hanig JP; Schmued LC; Paule MG
Neurotoxicology; 2014 Sep; 44():250-62. PubMed ID: 25064079
[TBL] [Abstract][Full Text] [Related]
3. Histopathological and electrophysiological indices of rotenone-evoked dopaminergic toxicity: Neuroprotective effects of acetyl-L-carnitine.
Sarkar S; Gough B; Raymick J; Beaudoin MA; Ali SF; Virmani A; Binienda ZK
Neurosci Lett; 2015 Oct; 606():53-9. PubMed ID: 26321151
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
Frau L; Borsini F; Wardas J; Khairnar AS; Schintu N; Morelli M
Synapse; 2011 Mar; 65(3):181-8. PubMed ID: 20665698
[TBL] [Abstract][Full Text] [Related]
5. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
Shao QH; Chen Y; Li FF; Wang S; Zhang XL; Yuan YH; Chen NH
Acta Pharmacol Sin; 2019 Dec; 40(12):1503-1512. PubMed ID: 31388087
[TBL] [Abstract][Full Text] [Related]
6. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
[TBL] [Abstract][Full Text] [Related]
7. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
[TBL] [Abstract][Full Text] [Related]
8. Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Bao XQ; Wu LY; Wang XL; Sun H; Zhang D
Naunyn Schmiedebergs Arch Pharmacol; 2015 May; 388(5):549-56. PubMed ID: 25678053
[TBL] [Abstract][Full Text] [Related]
9. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress.
Zhu YL; Sun MF; Jia XB; Cheng K; Xu YD; Zhou ZL; Zhang PH; Qiao CM; Cui C; Chen X; Yang XS; Shen YQ
Int Immunopharmacol; 2019 Jan; 66():19-27. PubMed ID: 30419450
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
12. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
13. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
15. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
Haga H; Matsuo K; Yabuki Y; Zhang C; Han F; Fukunaga K
Neurochem Int; 2019 Oct; 129():104492. PubMed ID: 31229554
[TBL] [Abstract][Full Text] [Related]
17. Poloxamer 188-mediated anti-inflammatory effect rescues cognitive deficits in paraquat and maneb-induced mouse model of Parkinson's disease.
Ding W; Lin H; Hong X; Ji D; Wu F
Toxicology; 2020 Apr; 436():152437. PubMed ID: 32169474
[TBL] [Abstract][Full Text] [Related]
18. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Goldberg NR; Haack AK; Lim NS; Janson OK; Meshul CK
Neuroscience; 2011 Apr; 180():256-71. PubMed ID: 21335067
[TBL] [Abstract][Full Text] [Related]
20. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
